07.01.06
$3.9 Billion
Key Executives:
Ludwig Georg Braun, Chairman of Management Board
H.C. Michael Ungethum, Vice Chairman, Aesculap Division
Caroll Neubauer, head of North American Region
Wolfgang Feller, head of B. Braun Avitum Division
Meinrad Lugan, head of OPM and Hospital Care divisions
Heinz-Walter GroBe, head of finance, taxes and controlling, corporate services
No. of Employees: 30,973
World Headquarters: Melsungen, Germany
The lone privately held medical device manufacturer in the Top 30 managed a slight rise in fiscal 2005 sales at 3%, despite the strong dollar.
In terms of the strong dollar, for instance, the Melsungen, Germany-based company was hurt in the earnings department as earnings increased by 14% in Euros; in dollars, the company actually dropped 7%.
While many medical device companies are making a big push in the high-growth region of Asia, B. Braun also continues to build in its growth area in Europe. More than half of the company’s 2005 sales came from Europe—including B. Braun’s home turf of Germany, which produced 23% of the company’s total sales.
And B. Braun is building on its stronghold in Europe after opening a state-of-the-art IV solution factory in Melsungen, Germany along with the expansion of a medical product manufacturing facility in Escholz-matt, Switzerland.
“Thanks to cutting edge technology and the contribution of our dedicated employees, with these two major investments, we have been able to create long-term competitive cost structures in Central Europe, particularly for basic hospital care products,” said Ludwig Georg Braun, chairman of the management board, B. Braun.
While the company did well in Germany, it faces several hurdles there, including extensive talk on social and fiscal reform along with the trend toward hospital privatization.
While Central and South America are B. Braun’s smallest regions, combined they offered the highest percentage of growth in 2005 with a 30% jump in revenues. The region benefited from the continued leadership from its core segments of surgical instruments and suture materials.
The North American region incorporates almost a quarter of the company’s total sales, having reached $852 million in 2005. The biggest drivers in the region were its orthopedic products, safety products and the Duplex, a dual chamber system for intravenous medical care. In the United States, where B. Braun operates one of the largest contract manufacturing businesses in the world in Bethlehem, PA, the company has developed revenue from its partnership with Premier, the largest hospital group purchasing organization.
After Central and South America, B. Braun grew the fastest in its Asia and Australian regions, with a 14% jump. These areas are benefiting from new plants in the last few years in the company’s surgical instruments sector. China is particularly noteworthy, as B. Braun opened the China Instruments Production plan in Suzhou, China in September 2005 and another plant, China Healthcare Infusions Elements Factory, is currently in development in Suzhou.
The company operates four major divisions: Hospital Care, Aesculap, Out Patient Market (OPM) and Avitum. The Avitum division was previously called the Medtech division, which manufactures dialysis machines.
The company’s main core of business is its Hospital Care division, which was bolstered by a few areas including peripheral IV catheters. The company also improved on its IV pump product line with the expansion and further adaptation of the Fluid Management Generation Space to meet the needs of hospitals with new and improved software.
In the Aesculap division, which manufactures surgical products, Eastern Europe and the North and Latin American markets fueled much of its success. In 2005, the division launched several new products, including the Metha hip short shaft prosthesis. The company also launched, in 2006, the aktivL IVD (intervertebral disk) prosthesis, a second generation of intervertebral disk implants, and the Univation knee endoprosthesis system.
In spite of all these positive developments, Aesculap has been hurt in China as a result of regulatory restrictions.
B. Braun made two acquisitions in fiscal 2005 in Tetec AG of Reutlingen, Germany and Ascalon. Tetec is a manufacturer of biological tissue replacement, while Ascalon is a manufacturer of the hollow fiber membranes.
Key Executives:
Ludwig Georg Braun, Chairman of Management Board
H.C. Michael Ungethum, Vice Chairman, Aesculap Division
Caroll Neubauer, head of North American Region
Wolfgang Feller, head of B. Braun Avitum Division
Meinrad Lugan, head of OPM and Hospital Care divisions
Heinz-Walter GroBe, head of finance, taxes and controlling, corporate services
No. of Employees: 30,973
World Headquarters: Melsungen, Germany
The lone privately held medical device manufacturer in the Top 30 managed a slight rise in fiscal 2005 sales at 3%, despite the strong dollar.
In terms of the strong dollar, for instance, the Melsungen, Germany-based company was hurt in the earnings department as earnings increased by 14% in Euros; in dollars, the company actually dropped 7%.
While many medical device companies are making a big push in the high-growth region of Asia, B. Braun also continues to build in its growth area in Europe. More than half of the company’s 2005 sales came from Europe—including B. Braun’s home turf of Germany, which produced 23% of the company’s total sales.
And B. Braun is building on its stronghold in Europe after opening a state-of-the-art IV solution factory in Melsungen, Germany along with the expansion of a medical product manufacturing facility in Escholz-matt, Switzerland.
“Thanks to cutting edge technology and the contribution of our dedicated employees, with these two major investments, we have been able to create long-term competitive cost structures in Central Europe, particularly for basic hospital care products,” said Ludwig Georg Braun, chairman of the management board, B. Braun.
While the company did well in Germany, it faces several hurdles there, including extensive talk on social and fiscal reform along with the trend toward hospital privatization.
While Central and South America are B. Braun’s smallest regions, combined they offered the highest percentage of growth in 2005 with a 30% jump in revenues. The region benefited from the continued leadership from its core segments of surgical instruments and suture materials.
The North American region incorporates almost a quarter of the company’s total sales, having reached $852 million in 2005. The biggest drivers in the region were its orthopedic products, safety products and the Duplex, a dual chamber system for intravenous medical care. In the United States, where B. Braun operates one of the largest contract manufacturing businesses in the world in Bethlehem, PA, the company has developed revenue from its partnership with Premier, the largest hospital group purchasing organization.
After Central and South America, B. Braun grew the fastest in its Asia and Australian regions, with a 14% jump. These areas are benefiting from new plants in the last few years in the company’s surgical instruments sector. China is particularly noteworthy, as B. Braun opened the China Instruments Production plan in Suzhou, China in September 2005 and another plant, China Healthcare Infusions Elements Factory, is currently in development in Suzhou.
The company operates four major divisions: Hospital Care, Aesculap, Out Patient Market (OPM) and Avitum. The Avitum division was previously called the Medtech division, which manufactures dialysis machines.
The company’s main core of business is its Hospital Care division, which was bolstered by a few areas including peripheral IV catheters. The company also improved on its IV pump product line with the expansion and further adaptation of the Fluid Management Generation Space to meet the needs of hospitals with new and improved software.
In the Aesculap division, which manufactures surgical products, Eastern Europe and the North and Latin American markets fueled much of its success. In 2005, the division launched several new products, including the Metha hip short shaft prosthesis. The company also launched, in 2006, the aktivL IVD (intervertebral disk) prosthesis, a second generation of intervertebral disk implants, and the Univation knee endoprosthesis system.
In spite of all these positive developments, Aesculap has been hurt in China as a result of regulatory restrictions.
B. Braun made two acquisitions in fiscal 2005 in Tetec AG of Reutlingen, Germany and Ascalon. Tetec is a manufacturer of biological tissue replacement, while Ascalon is a manufacturer of the hollow fiber membranes.